CMED
8.4.2014 17:38:29 CEST | Business Wire | Pressemeddelelse
Cmed, a full service CRO specialized in the design and delivery of both innovative and traditional early phase I to IIb patient clinical trials, has been invited to share its early phase clinical research expertise at leading industry events in the coming months.
Geoff Fatzinger, Cmed’s Vice President of Global Medical and Regulatory Affairs, is presenting the session “Adaptive Trials: A Global Regulatory Perspective” at Smart Trials 2014 in London, UK, on Wednesday April 9 at 2.30pm GMT. Geoff’s presentation will take an overview of adaptive designs in early phase clinical trials and the benefits this approach can bring, with a particular focus on regulatory issues and key components which must be considered when implementing an adaptive design. Conference attendees are also encouraged to visit Cmed in the exhibit hall.
Joanne Hollenbach, Cmed’s Chief Operating Officer, US, will be presenting at the Outsourcing in Clinical Trials East Coast conference in Philadelphia, USA on May 13 at 4pm EST. The presentation entitled “How to Determine the Feasibility of a Proposed Alternative Clinical Monitoring Strategy” will provide a rationale for Risk Based Monitoring and explore when it is appropriate and when it is not, as well as explain the limits of Risk Based Monitoring, even in trials where it is appropriate to use. Attendees will be able to hear more from Joanne on booth No. 13.
Cmed will be announcing further expert presentations at industry leading events in the coming weeks.
Cmed's approach has been to build an organization in response to the current challenges being faced by the biopharmaceutical industry, with specialist capabilities and expertise, readily available to support the industry through the design and operational delivery of traditional, innovative and/or complex early Phase I to IIb clinical trials, as well as Phase III studies. Cmed accomplishes this through deep regulatory and medical insight, superior drug development consulting, robust clinical operations, in-depth biometrics solutions, as well its in-house eClinical technology, Timaeus.
To pre-arrange a meeting with Cmed at Smart Trials 2014 or Outsourcing in Clinical Trials East Coast, email info@cmedresearch.com .
- ends-
About Cmed Group ( www.CmedGroup.com )
Cmed Group is an innovative clinical trials services and advanced software provider which includes two divisions: Cmed Clinical Services and Cmed Technology.
Cmed Clinical Services ( www.CmedResearch.com ) is a CRO that provides full service trial delivery teams (project management, clinical monitoring, data management, biostatistics, medical affairs, regulatory, consulting, and medical writing services) as well as stand-alone solutions across all its services, including Biometrics functional services. It combines experience with using many commercially available technologies but also uses trusted and innovative software developed by Cmed Technology, including its award winning system, Timaeus.
Cmed Technology ( www.CmedTechnology.com ) offers Timaeus: a single platform for electronic trial design, paper and electronic data capture, monitoring, coding, data management and reporting. Timaeus, which uses advanced distributed cloud computing and mobile technologies, is designed to respond on-demand to the needs of investigators, data managers and study teams. Timaeus has been used in every phase of clinical research – including early phase, pivotal and late phase studies as well as in emerging markets.
Contact:
Cmed
Anna Forster
+44 (0)1403 756471
aforster@cmedresearch.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
Andersen Global lancerer Andersen in Pakistan16.4.2026 22:57:00 CEST | Pressemeddelelse
Andersen Global fortsætter sin regionale vækst i Sydasien med tilføjelsen af Andersen in Pakistan som det seneste medlemsfirma, der slutter sig til den globale organisation. Efter overgangen til Andersen-brandet tilbyder virksomheden – tidligere kendt som Saafin Global Consulting – en bredt funderet praksis, der betjener kunder på tværs af brancher, herunder fremstillingsindustri, energi, finansielle tjenester, telekommunikation, sundhedsvæsen, fast ejendom og private equity. Med hovedkvarter i Islamabad leverer Andersen in Pakistan integreret support inden for skat, virksomhedsrådgivning og HR-tjenester til nationale og internationale organisationer. "Vores service er forankret i etik, styret af gennemsigtighed og bevist gennem et vedholdende engagement i præcision," udtalte Rashid Ibrahim, ledende partner hos Andersen in Pakistan. "At tage Andersen-brandet til os er en vigtig milepæl for vores firma. Det afspejler vores forpligtelse til at levere praktiske løsninger af høj kvalitet,
BTG Pactual Timberland Investment Group Completes First Close of US$ 370 Million to Newest Core Latin American Timberland Strategy16.4.2026 22:04:00 CEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, announced today that it has completed the first close of US$ 370 million in commitments to its newest core Latin America strategy. Targeting investment of US$ 1.5 billion over 5 years, the strategy focuses on large-scale, sustainably managed, core timberland assets across Chile, Uruguay and Brazil, and seeks diversification across geography, climatic zones, species, and end-markets. BTG Pactual TIG has operated in Latin America for over two decades, and has built and managed a series of scaled timberland platforms through this strategy, including the creation of three platform companies, Lumin, Vista Hermosa, and Plateau, forming part of the firm’s global US$ 7.5 billion portfolio. The formation of Plateau, announced in August 2025, marked the first acquisition under this new strategy. Created in partnership with Klabin S.A. (Klabin) and British Columbia Investment Mana
Multi-Color Corporation Announces Confirmation of Plan of Reorganization16.4.2026 19:55:00 CEST | Press release
Company Expects to Emerge from Prepackaged Chapter 11 in Coming Weeks With Significantly Deleveraged Balance Sheet Including Approximately $3.8 Billion Reduction in Outstanding Funded DebtSignificant New Money Investment Will Establish Strong Liquidity Position to Support Long-Term Growth and Investment Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that the United States Bankruptcy Court for the District of New Jersey (the “Court”) has confirmed the Company’s prepackaged plan of reorganization (the “Plan”). MCC expects to emerge from prepackaged Chapter 11 in the coming weeks. Under the terms of the Plan, MCC will complete a comprehensive restructuring transaction that significantly deleverages the Company’s balance sheet and recapitalizes the business. The restructuring reduces net debt by approximately $3.8 billion, reduces annualized cash interest expense by more than $330 million, and extends long‑term debt maturities to
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide8.4.2026 18:00:00 CEST | Press release
Part of the Visa Intelligent Commerce portfolio, Intelligent Commerce Connect will enable more ways for agents to pay and merchants to accept agentic transactions in a single integrationCurrently in pilot with select partners including Aldar, AWS, Diddo, Highnote, Mesh, Payabli, Sumvin, and rolling out to more partners this year Visa Inc. (NYSE: V) today unveiled Intelligent Commerce Connect, a new solution that makes it easier for businesses to connect to and participate in AI-powered commerce. Intelligent Commerce Connect acts as a network, protocol, and token vault-agnostic ‘on ramp’ to agentic commerce for agent builders, merchants, and enablers. As consumers increasingly rely on AI agents to make purchases, businesses – whether they are building agents, selling to them, or processing transactions – need a simple way to get started. Intelligent Commerce Connect, part of the Visa Intelligent Commerce portfolio, meets that need. Through a single integration via the Visa Acceptance Pl
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
